No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KOD Kodiak Sciences
- 2.610
- -0.080-2.97%
Close Jun 18 16:00 ET
- 2.520
- -0.090-3.45%
Post 19:39 ET
137.12MMarket Cap-587P/E (TTM)
2.690High2.590Low143.91KVolume2.690Open2.690Pre Close377.85KTurnover0.45%Turnover RatioLossP/E (Static)52.53MShares7.84052wk High0.57P/B84.17MFloat Cap1.37052wk Low--Dividend TTM32.25MShs Float171.210Historical High--Div YieldTTM3.72%Amplitude1.370Historical Low2.625Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences (KOD) Receives a Sell From Barclays
Express News | Kodiak Sciences Inc : Jefferies Cuts Target Price to $4 From $7
Kodiak Sciences | 10-Q: Quarterly report
Express News | Kodiak Sciences Inc - Believe That Our Current Cash Will Support Our Current and Planned Operations Into 2026
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
$Kodiak Sciences(KOD.US$
NEWS
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
NEWS
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
2
$Kodiak Sciences(KOD.US$
NEWS
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
NEWS
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Who is the winner today, after the poditive data announced on 03 Feb
$EyePoint Pharmaceuticals(EYPT.US$
$Adverum Biotechnologies(ADVM.US$
$Regenxbio(RGNX.US$
$4D Molecular Therapeutics(FDMT.US$
$Kodiak Sciences(KOD.US$
$EyePoint Pharmaceuticals(EYPT.US$
$Adverum Biotechnologies(ADVM.US$
$Regenxbio(RGNX.US$
$4D Molecular Therapeutics(FDMT.US$
$Kodiak Sciences(KOD.US$
$Kodiak Sciences(KOD.US$ announced first time results of KSI-501 ABC Phase 1 study. The data outlined safety and biocativity of KSI-501, along with high binding affinity and bioactivity against VEGF and IL-6.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg